Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drugs and the fetus.

Phillipa M Kyle1

  • 1Obstetrics and Gynaecology, Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand. pippa.kyle@chmeds.ac.nz

Current Opinion in Obstetrics & Gynecology
|April 8, 2006
PubMed
Summary

Drug safety in pregnancy requires ongoing evaluation. While some medications like anti-nausea therapies and certain antidepressants appear safe, others like statins and angiotensin II inhibitors should be avoided during pregnancy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database.

Pregnancy hypertension·2015
Same author

A new direction for prenatal chromosome microarray testing: software-targeting for detection of clinically significant chromosome imbalance without equivocal findings.

PeerJ·2014
Same author

PIERS proteinuria: relationship with adverse maternal and perinatal outcome.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2011
Same author

Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model.

Lancet (London, England)·2010
Same author

Aetiology and pathogenesis of IUGR.

Best practice & research. Clinical obstetrics & gynaecology·2009
Same author

Reassuring fetal middle cerebral artery doppler velocimetry in alloimmunised pregnancies: neonatal outcomes without invasive procedures.

Fetal diagnosis and therapy·2005

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Maternal-Fetal Medicine

Background:

  • Limited licensed medications exist for use during pregnancy.
  • Increased use of novel drug classes in pregnancy due to efficacy and tolerability demonstrated outside of pregnancy.
  • Existing drug safety data in pregnancy is predominantly retrospective and lacks robust control.

Purpose of the Study:

  • To review current data on the safety and efficacy of various drug classes during pregnancy.
  • To provide guidance on medication use in pregnant individuals based on recent findings.
  • To highlight areas where further research is critically needed.

Main Methods:

  • Review of recent clinical findings and trial data on drug use in pregnancy.
  • Analysis of safety profiles for common and novel therapeutic agents.
  • Assessment of risks associated with specific drug classes and combinations.

Main Results:

  • Anti-nausea drugs, H2-receptor antagonists, and proton pump inhibitors show favorable safety profiles.
  • Metformin shows promise for gestational diabetes; statins are contraindicated in early pregnancy.
  • New antiepileptics have low abnormality risks, but combination with valproate increases risk.
  • Selective serotonin reuptake inhibitors (SSRIs) appear safe for teratogenesis but may cause neonatal behavioral syndrome.
  • Angiotensin II inhibitors are not recommended in the second and third trimesters; smoking cessation programs require reevaluation.

Conclusions:

  • Continued vigilance and information sharing regarding drug safety in pregnancy are essential.
  • The risk-benefit assessment for many drugs in pregnancy remains uncertain pending large-scale clinical trials.
  • Prescribing decisions require careful consideration of individual patient factors and the latest evidence.

Related Experiment Videos